R3TA

Obesity Management

R3TA is most notably being developed for weight loss. In clinical trials, it has demonstrated the potential to help individuals lose over 20% of their body weight. This is a significant breakthrough, particularly for people who have not had success with traditional weight loss methods or other weight loss medications. By targeting multiple metabolic pathways, R3TA offers a more comprehensive solution to managing obesity.

Type 2 Diabetes Treatment

In addition to obesity, R3TA is being tested for its effectiveness in type 2 diabetes management. The drug helps regulate blood sugar levels while also promoting weight loss, which is crucial for people with type 2 diabetes. With better control over glucose and weight, patients may experience improved long-term outcomes and easier management of their diabetes.

Treats Fatty Liver Disease

Another promising area of research for R3TA is its potential to treat fatty liver disease. Early studies indicate that the drug may help reduce liver fat in people with obesity, potentially preventing the progression of non-alcoholic fatty liver disease. This dual action on both weight and liver fat makes R3TA a unique treatment option for those at risk of liver complications.

What Makes R3TA Unique?

R3TA represents a major breakthrough in weight loss journeys. Unlike earlier treatments like Wegovy or Mounjaro, which focus on one or two hormone receptors, R3TA targets three. This makes it a triple agonist, interacting with the following receptors to promote fat burning, blood sugar control, and appetite reduction:

• GLP-1 (Glucagon-like peptide 1)

• GIP (Glucose-dependent insulinotropic polypeptide)

• GCG (Glucagon)

Weekly Injection with Long-Lasting Effects

Administered as a weekly injection, R3TA stays active in the body for around six days. This extended half-life ensures long-lasting effects, making it a convenient option for patients who struggle with daily medication.

How Does R3TA Work?

R3TA works by mimicking the actions of three important hormones such as GLP-1, GIP and GCG. These hormones play a crucial role in regulating hunger, fat metabolism, and blood sugar levels. By targeting multiple receptors, R3TA aims to provide more comprehensive effects than other medications that focus on only one or two pathways. Here’s a detailed look at the specific actions of each hormone receptor involved:

• GLP-1 (Glucagon-like peptide-1): This receptor is responsible for reducing appetite and slowing down the digestion process. By doing so, it helps people feel fuller for a longer period of time, which can lead to a reduction in calorie intake and promote weight loss.

• GIP (Gastric inhibitory polypeptide): This hormone plays a key role in lowering blood sugar levels, particularly after eating a meal. Additionally, it contributes to improved fat metabolism, helping the body process and store fat more efficiently, which can aid in weight management.

• GCG (Glucagon): The glucagon receptor encourages the body to burn stored fat for energy. By promoting fat burning, it helps increase calorie expenditure and supports the reduction of body fat, contributing to overall weight loss and improved metabolic health.

By acting on all three of these receptors, R3TA offers a multi-pronged approach to weight loss and metabolic control, making it a promising treatment option for individuals struggling with obesity or metabolic conditions such as type 2 diabetes.

Together, these actions not only reduce calorie intake but also promote weight loss by improving metabolic efficiency.

Potential Side Effects

As with any medication, R3TA has potential side effects. However, these tend to be mild to moderate and occur mainly during the initial dosing period. The most commonly reported side effects include:

• Nausea

• Diarrhoea

• Vomiting

• Mild stomach discomfort

Importantly, no cases of severe hypoglycemia or fatalities were reported during clinical trials, and most side effects were resolved without needing to stop the medication.

Dosing & Reconstitution Guide

Educational guide for reconstitution and weekly dosing